Brought to you by 
Eleven partners IL-6 antagonist assets with Roche
15 Sep 2017
Executive Summary
Eleven Biotherapeutics Inc. licensed Roche exclusive global rights to its preclinical ophthalmic antibody EBI031, plus all of its IL-6 antagonist antibody technology. Roche has a license to patents and know-how, plus the right to sublicense.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eleven partners IL-6 antagonist assets with Roche
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice